Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
Castle Biosciences (Nasdaq: CSTL), a company focused on improving health through innovative diagnostic tests, has announced the release date for its third quarter 2024 financial results. The company will disclose its financial performance for the quarter and nine months ended Sept. 30, 2024, after market close on Monday, Nov. 4, 2024.
Following the release, Castle Biosciences will host a conference call and webcast at 4:30 p.m. Eastern time on the same day to discuss the results. Interested parties can access the live webcast through the provided link or via the Investor Relations page on the company's website. For those joining by phone, dial-in details for both U.S. and international participants are provided, along with the access code. A brief Q&A session will follow management's commentary.
Castle Biosciences (Nasdaq: CSTL), un'azienda focalizzata sul miglioramento della salute attraverso test diagnostici innovativi, ha annunciato la data di rilascio dei propri risultati finanziari del terzo trimestre 2024. L'azienda divulgherà le sue performance finanziarie per il trimestre e i nove mesi conclusi il 30 settembre 2024, dopo la chiusura del mercato di lunedì 4 novembre 2024.
Dopo la divulgazione, Castle Biosciences ospiterà una chiamata e webcast conferenza alle 16:30, ora orientale lo stesso giorno per discutere i risultati. Le parti interessate possono accedere al webcast dal vivo tramite il link fornito o attraverso la pagina delle Relazioni con gli Investitori sul sito web dell'azienda. Per coloro che partecipano telefonicamente, sono forniti i dettagli per la connessione sia per i partecipanti statunitensi che internazionali, insieme al codice di accesso. Seguirà una breve sessione di domande e risposte dopo il commento della direzione.
Castle Biosciences (Nasdaq: CSTL), una empresa enfocada en mejorar la salud a través de pruebas diagnósticas innovadoras, ha anunciado la fecha de publicación de sus resultados financieros del tercer trimestre de 2024. La empresa dará a conocer su desempeño financiero para el trimestre y los nueve meses que terminaron el 30 de septiembre de 2024, al cierre del mercado el lunes 4 de noviembre de 2024.
Después de la publicación, Castle Biosciences llevará a cabo una llamada conferencial y webcast a las 4:30 p.m. hora del este el mismo día para discutir los resultados. Las partes interesadas pueden acceder al webcast en vivo a través del enlace proporcionado o mediante la página de Relaciones con Inversores en el sitio web de la empresa. Para quienes se unan por teléfono, se proporcionan los detalles de conexión tanto para participantes de EE. UU. como internacionales, junto con el código de acceso. Después del comentario de la dirección, se realizará una breve sesión de preguntas y respuestas.
Castle Biosciences (Nasdaq: CSTL)는 혁신적인 진단 테스트를 통해 건강을 개선하는 데 초점을 맞춘 회사로, 2024년 3분기 재무 결과 발표 날짜를 발표했습니다. 회사는 2024년 9월 30일로 종료되는 분기 및 아홉 달 동안의 재무 성과를 2024년 11월 4일 월요일 시장 종료 후 공개할 예정입니다.
발표 후, Castle Biosciences는 같은 날 동부 표준시 오후 4시 30분에 결과 논의를 위한 컨퍼런스 콜 및 웹캐스트를 개최합니다. 관심 있는 분들은 제공된 링크를 통해 실시간 웹캐스트에 접속하거나 회사 웹사이트의 투자자 관계 페이지를 통해 접속할 수 있습니다. 전화로 참가하는 분들을 위해 미국 및 국제 참가자 모두에 대한 다이얼인 정보와 액세스 코드가 제공됩니다. 관리자의 설명 후 간단한 질문 및 답변 세션이 이어질 것입니다.
Castle Biosciences (Nasdaq: CSTL), une entreprise axée sur l'amélioration de la santé grâce à des tests diagnostiques innovants, a annoncé la date de publication de ses résultats financiers du troisième trimestre 2024. L'entreprise divulguera ses performances financières pour le trimestre et les neuf mois se terminant le 30 septembre 2024, après la fermeture du marché le lundi 4 novembre 2024.
Suite à la publication, Castle Biosciences animera un appel Web et conférence à 16h30, heure de l'Est le même jour pour discuter des résultats. Les parties intéressées peuvent accéder au webinaire en direct via le lien fourni ou via la page des Relations Investisseurs sur le site web de l'entreprise. Pour ceux qui se joignent par téléphone, les détails de connexion pour les participants américains et internationaux sont fournis, ainsi que le code d'accès. Une brève session de questions-réponses suivra le commentaire de la direction.
Castle Biosciences (Nasdaq: CSTL), ein Unternehmen, das sich auf die Verbesserung der Gesundheit durch innovative diagnostische Tests konzentriert, hat das Veröffentlichungsdatum für seine Finanzergebnisse des dritten Quartals 2024 bekannt gegeben. Das Unternehmen wird seine finanzielle Leistung für das Quartal und die neunten Monate, die am 30. September 2024 endeten, nach Marktschluss am Montag, den 4. November 2024, bekannt geben.
Nach der Veröffentlichung wird Castle Biosciences um 16:30 Uhr Eastern Time am selben Tag eine Telefonkonferenz und einen Webcast veranstalten, um die Ergebnisse zu erörtern. Interessierte können über den bereitgestellten Link auf den Live-Webcast zugreifen oder die Investor-Relations-Seite der Unternehmenswebsite besuchen. Für die telefonische Teilnahme werden sowohl für US-amerikanische als auch für internationale Teilnehmer die Einwahl-Details sowie der Zugangscode bereitgestellt. Es wird eine kurze Frage-und-Antwort-Runde auf das Managementkommentar folgen.
- None.
- None.
Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
Conference Call and Webcast Details
A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/435529710, or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.
To access the live conference call via phone, please dial 1 833 470 1428 from
There will be a brief Question and Answer session following management commentary.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014641704/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When will Castle Biosciences (CSTL) release its Q3 2024 financial results?
What time is Castle Biosciences' (CSTL) Q3 2024 earnings conference call?
How can I access Castle Biosciences' (CSTL) Q3 2024 earnings call?
Will there be a Q&A session during Castle Biosciences' (CSTL) Q3 2024 earnings call?
